Allotransplantation for Patients Age >= 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival

Brian L. McClune, Kwang Woo Ahn, Hai-Lin Wang, Joseph H. Antin, Andrew S. Artz, Jean-Yves Cahn, Abhinav Deol, Cesar O. Freytes, Mehdi Hamadani, Leona A. Holmberg, Madan H. Jagasia, Ann A. Jakubowski, Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Alan M. Miller, Richard Olsson, Tanya L. Pedersen, Joseph Pidala, Michael A. Pulsipher, Jacob M. RoweWael Saber, Koen W. van Besien, Edmund K. Waller, Mahmoud D. Aljurf, Goergun Akpek, Ulrike Bacher, Nelson J. Chao, Yi-Bin Chen, Brenda W. Cooper, Jason Dehn, Marcos J. de Lima, Jack W. Hsu, Ian D. Lewis, David I. Marks, Joseph McGuirk, Mitchell S. Cairo, Harry C. Schouten, Jeffrey Szer, Muthalagu Ramanathan, Bipin N. Savani, Matthew Seftel, Gerard Socie, Ravi Vij, Erica D. Warlick, Daniel J. Weisdorf*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Non-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often undergo allogeneic hematopoietic cell transplantation (HCT). We analyzed Center for International Blood and Marrow Transplant Research data on 1248 patients age ?40 years receiving reduced-intensity conditioning (RIC) or nonmyeloablative (NMA) conditioning HCT for aggressive (n = 668) or indolent (n = 580) NHL. Aggressive lymphoma was more frequent in the oldest cohort 49% for age 40 to 54 versus 57% for age 55 to 64 versus 67% for age ?65; P = .0008). Fewer patients aged ?65 had previous autografting (26% versus 24% versus 9%; P = .002). Rates of relapse, acute and chronic GVHD, and nonrelapse mortality (NRM) at 1 year post-HCT were similar in the 3 age cohorts (22% [95% confidence interval (CI), 19% to 26%] for age 40 to 54, 27% [95% CI, 23% to 31%] for age 55 to 64, and 34% [95% CI, 24% to 44%] for age ?65. Progression-free survival (PFS) and overall survival (OS) at 3 years was slightly lower in the older cohorts (OS: 54% [95% CI, 50% to 58%] for age 40 to 54; 40% [95% CI, 36% to 44%] for age 55 to 64, and 39% [95% CI, 28% to 50%] for age ?65; P <.0001). Multivariate analysis revealed no significant effect of age on the incidence of acute or chronic GVHD or relapse. Age ?55 years, Karnofsky Performance Status
Original languageEnglish
Pages (from-to)960-968
JournalBiology of Blood and Marrow Transplantation
Issue number7
Publication statusPublished - Jul 2014


  • Reduced intensity
  • Nonmyeloablative
  • Allogeneic
  • Hematopoietic cell transplantation
  • Elderly
  • Lymphoma

Cite this